Highlights Fuji Pharma Co., Ltd.

Equities

4554

JP3816200004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-28 EDT			5-day change	1st Jan Change
1,474 ^JPY	-1.73%		-2.90%	-15.24%

2023	Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	MT
2023	Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ex-dividend day for interim dividend	03-27	FA
Final dividend	23-09-27	FA
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-05	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	23-08-15	CI
Fuji Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	23-05-11	CI
Ex-dividend day for interim dividend	23-03-29	FA
Alvotech, Fuji Pharma Include New Biosimilar Candidate in Marketing Partnership in Japan	23-01-13	MT
Alvotech and Fuji Pharma Expands Partnership Adding A New Biosimilar Candidate	23-01-13	CI
Fuji Pharma Co., Ltd. Submits Application for Marketing Approval of First Biosimilar Candidate in Japan	22-10-17	CI
Ex-dividend day for final dividend	22-09-28	FA
Ex-dividend day for interim dividend	22-03-29	FA
Fuji Pharma Co., Ltd. Provides Financial Guidance for the Fiscal Year Ending September 30, 2022	21-11-18	CI
Fuji Pharma Provides Dividend Guidance for the Fiscal Year Ending September 30, 2022	21-11-18	CI
Ex-dividend day for final dividend	21-09-28	FA
Fuji Pharma Co., Ltd. Announces Consolidated Earnings Results for the First Half of Fiscal Year Ending September 30, 2021	21-05-20	CI
Ex-dividend day for interim dividend	21-03-29	FA
Tranche Update on Fuji Pharma Co., Ltd.'s Equity Buyback Plan announced on February 9, 2021.	21-02-09	CI
Fuji Pharma Co., Ltd.'s Equity Buyback announced on February 9, 2021, has expired with 6,875,000 shares, representing 22.06% for ¥9,391.25 million.	21-02-09	CI
Fuji Pharma Co., Ltd. announces an Equity Buyback for 7,320,600 shares, representing 23.47% for ¥10,000 million.	21-02-09	CI
Fuji Pharma Co., Ltd. authorizes a Buyback Plan.	21-02-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fuji Pharma Co., Ltd.

Equities

4554

JP3816200004

Highlights

Filters